OR WAIT null SECS
Growth and Advancements in Fill/Finish
Employing novel technologies and more patient-centric approaches
Delving into Biopharmaceutical Development and Manufacturing
Quality Considerations in Changing Excipient Providers
January 09, 2024
The expansion will boost solid-phase peptide synthesis total reactor volume to 32,000 L.
January 08, 2024
Societal™ CDMO's J. David Enloe and Erica Raether discuss the fundamentals of maintaining a strong company culture during times of change.
January 05, 2024
MediWound has been granted an additional $6.7 million by the DoD to advance NexoBrid as a non-surgical field care solution for the US military.
Under the collaboration, Boehringer Ingelheim and Ribo will develop RNA-based therapeutics to treat NASH/MASH.
January 04, 2024
Roche will acquire select parts of the LumiraDx group related to that company’s point-of-care technology, which integrates multiple tests on a single instrument.
AstraZeneca’s acquisition of Gracell includes a clinical-stage autologous cell therapy targeting hematologic malignancies and autoimmune diseases and a proprietary manufacturing platform.
The new Europe headquarters will be the hub for the company’s European operations, including production of product.
January 03, 2024
Revolutionary therapies restructure pharmaceutical manufacturing.
European bio/pharma companies have no choice but to invest and adapt to the evolving industry needs.
There are positive indications for future growth.